Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot therapy helps stroke patients regain arm movement

NCT ID NCT06870682

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a new robot-based therapy program to improve arm function in 10 people who had a stroke at least 6 months ago. The program combined robot-assisted training, practice with daily activities, and home exercises over 4 weeks. The goal was to see if the approach is feasible and potentially helpful for improving movement and sensation in the affected arm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
robot-based upper limb rehabilitation program
What this could lead to
If this approach works, it could point toward a new therapy to improve arm and hand function in people who have had a stroke.
What could go wrong
This is a very small pilot study with only 10 participants, so results may not apply to everyone. The therapy is intensive and requires frequent visits, which may not be feasible for all stroke survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Feb 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent must be obtained prior to any screening procedures 2. A first-ever unilateral, supra-tentorial stroke, as defined by WHO (rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin) 3. ≥18 years old 4. Being in the chronic phase after stroke, i.e. \> 6 months post stroke 5. Motor impairment in the upper limb, defined as Fugl-Meyer score \>22 out of 66 to demonstrate moderate to full upper limb motor function (patients scoring \<23 out of 66 will not be able to comply with the KINARM protocol) 6. Residual sensory upper limb impairment, defined as Tactile Discrimination Test score \<24 out of 25 7. Impaired functionality, defined as Action Research Arm Test score \<52 out of 57 8. Manageable spasticity for KINARM tasks Exclusion Criteria: 1. Having musculoskeletal and/or other neurological disorders impacting care or prognosis 2. Having severe communication or cognitive deficits that interfere with the protocol 3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP 4. Contraindications for robot-based therapy (e.g., uncontrolled epilepsy) 5. Participation in another clinical investigation 6. Having uncontrolled head movements (e.g. tremor), only relevant if participant is willing to receive the additional fNIRS assessments 7. Having any contra-indications for MRI, only relevant if participant is willing to receive the additional MRI assessments: * Pacemaker * Implantable Cardioverter Defibrillator (ICD) * Cochlear implant * Internal Insulin-pump * Deep brain stimulation * Any other metal device in body * Claustrophobia * Having a history of a neuropsychiatric or neurologic disorder before the diagnosis of stroke (e.g., depression, traumatic brain injury) * Use of psychoactive medication before the diagnosis of stroke (e.g., anti-depressive medication) * Use (or history of use) of drugs/alcohol * Being pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • KU Leuven

    Leuven, 3001, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.